LeukemiaNCT01004640
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial
An observational study of Leukemia, run by Alliance for Clinical Trials in Oncology at 161 sites in United States.
Trial summary
RATIONALE: Studying samples of blood and bone marrow from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at blood and bone marrow samples in patients with chronic myelogenous leukemia enrolled on a CALGB clinical trial. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Leukemia
- What is being tested?
- DNA analysis, Southern blotting and cytogenetic analysis
- How many people
- 60 participants
- Where
- 161 sitesUnited States
- Study dates
- 15 Dec 1998to Feb 2001
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: PATIENTS ENTERED ONTO CALGB TREATMENT STUDIES FOR CML
Who may be able to join
- Clinical diagnosis of chronic myelogenous leukemia (CML)
- Concurrent enrollment on a CALGB treatment protocol for newly diagnosed or previously treated CML (e.g, CLB-19804)
- Must not have initiated study therapy
Who cannot join
None listed.
Trial locations and contacts
161 sites in 1 country.
161 sites in 1 country
United States161 sites
Mission Hospital-Memorial Campus
Asheville, North Carolina, 28801
Mission Hospital-Saint Joseph Campus
Asheville, North Carolina, 28801
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, 21201
University of Maryland/Greenebaum Cancer Center
Baltimore, Maryland, 21201
CancerCare of Maine at Eastern Maine Medical Center
Bangor, Maine, 04401
Eastern Maine Medical Center, Bangor
Bangor, Maine, 04401
Central Vermont Medical Center/ National Life Cancer Treatment
Berlin Corners, Vermont, 05602
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61701
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Massachusetts General Hospital
Boston, Massachusetts, 02114
Brigham and Women's Hospital
Boston, Massachusetts, 02115
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
Roswell Park Cancer Institute
Buffalo, New York, 14263
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
University of Vermont College of Medicine
Burlington, Vermont, 05405
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Graham Hospital Assocation
Canton, Illinois, 29605
Illinois CancerCare-Canton
Canton, Illinois, 61520
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Memorial Hospital
Carthage, Illinois, 62321
Physicians' Clinic of Iowa PC
Cedar Rapids, Iowa, 52402
Mercy Hospital
Cedar Rapids, Iowa, 52403
Saint Luke's Hospital
Cedar Rapids, Iowa, 54202
University of North Carolina
Chapel Hill, North Carolina, 27599
Medical University of South Carolina
Charleston, South Carolina, 29425
Carolinas Medical Center, Charlotte
Charlotte, North Carolina, 28203
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, 28204
Mount Sinai Hospital Medical Center
Chicago, Illinois, 60608
University of Illinois Cancer Center
Chicago, Illinois, 60612-7243
Jesse Brown Veterans Affairs Medical Center
Chicago, Illinois, 60612
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Weiss Memorial Hospital
Chicago, Illinois, 60640
Valley Regional
Claremont, New Hampshire, 03743
Missouri Cancer Associates
Columbia, Missouri, 65201
Veterans Administration
Columbia, Missouri, 65201
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
University of Missouri - Ellis Fischel,
Columbia, Missouri, 65212
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, 43210
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Danville Regional Medical Center
Danville, Virginia, 24541
Duke University Medical Center
Durham, North Carolina, 27710
Greenville Health System Cancer Institute-Easley
Easley, South Carolina, 29640
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital Cancer Program at Union Hospital
Elkton, Maryland, 21921
Elmhurst Hospital Center
Elmhurst, New York, 11373
Eureka Hospital
Eureka, Illinois, 61530
Illinois CancerCare-Eureka
Eureka, Illinois, 615330
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, 46845
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Illinois CancerCare Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Illinois CancerCare-Cottage
Galesburg, Illinois, 61761
Glens Falls Hospital
Glens Falls, New York, 12801
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Illinois Oncology Limited
Granite City, Illinois, 62040
Saint Francis Hospital
Greenville, South Carolina, 29601
Greenville Health System Cancer Institute-Andrews
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Butternut
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Faris
Greenville, South Carolina, 29605
Greenville Memorial Hospital
Greenville, South Carolina, 29605
Greenville Health System Cancer Institute-Eastside
Greenville, South Carolina, 29615
Self Regional Healthcare
Greenwood, South Carolina, 29646
Cancer Centers of the Carolinas-Green Medial Oncology
Greer, South Carolina, 29650
Illinois CancerCare-Havana
Havana, Illinois, 62644
Mason District Hospital
Havana, Illinois, 62644
Memorial Healthcare System - Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Hopedale Medical Complex - Hospital, Hopedale
Hopedale, Illinois, 61847
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, 52242-1002
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Queens Hospital Center
Jamaica, New York, 11432
Capital Regional Medical Center
Jefferson City, Missouri, 65101
Jupiter Medical Center
Jupiter, Florida, 33548
Cheshire Medical Center-Dartmouth-Hitchcock Keene
Keene, New Hampshire, 03431
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Kewanee Hospital
Kewanee, Illinois, 61443
Kinston Medical Specialists
Kinston, North Carolina, 28501
Lenoir Memorial Hospital
Kinston, North Carolina, 28501
Community Howard Regional Health
Kokomo, Indiana, 46904
IU Health La Porte Hospital
La Porte, Indiana, 46350
Weeks Memorial Hospital
Lancaster, New Hampshire, 03584
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada, 89106
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756
Alice Peck Day Memorial Hospital
Lebanon, New Hampshire, 03766
Beebe Medical Center
Lewes, Delaware, 19958
Saint Barnabas Medical Center
Livingston, New Jersey, 07039
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Mcdonough District Hospital
Macomb, Illinois, 61455
Baptist Memorial Hospital and Cancer Center-Memphis
Memphis, Tennessee, 38120
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Saint Joseph Regional Medical Center - Mishawaka
Mishawaka, Indiana, 46545-1470
Holy Family Medical Center
Monmouth, Illinois, 61462
Illinois CancerCare-Monmouth
Monmouth, Illinois, 61462
Mount Sinai Medical Center
New York, New York, 10029
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065
Weill Medical College of Cornell University
New York, New York, 10065
Christiana Care Health Services
Newark, Delaware, 19718
North Country Health
Newport, Vermont, 05855
Community Cancer Center Foundation
Normal, Illinois, 61761
Illinois CancerCare-Community Cancer Center
Normal, Illinois, 61761
Bromenn Regional Medical Center
Normal, Illinois, 61861
Oswego Hospital
Oswego, New York, 13126
Illinois CancerCare- Ottawa Clinic
Ottawa, Illinois, 61350
Ottwa Regional Hospital and Healthcare
Ottawa, Illinois, 61350
Illinois CancerCare- Pekin
Pekin, Illinois, 61554
Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Pekin Hospital
Pekin, Illinois, 61554
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
Illinois CancerCare- Peoria
Peoria, Illinois, 61615
Illinois Oncology Research Association-CCOP
Peoria, Illinois, 61615
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois CancerCare- Peru
Peru, Illinois, 61354
Illinois Valley Hospital
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
Pittsburgh, Pennsylvania, 15224-1791
West Penn Hospital
Pittsburgh, Pennsylvania, 15224
Illinois CancerCare- Princeton
Princeton, Illinois, 61356
Perry Memorial Hospital
Princeton, Illinois, 61356
Frisbie Hospital
Rochester, New Hampshire, 03867
Sarah Culberston Memorial Hospital
Rushville, Illinois, 62681
Northeastern
Saint Johnsbury, Vermont, 05819
Oncology Care Associates PLLC
Saint Joseph, Michigan, 49085
Lakeland Hospital
Saint Joseph, Missouri, 49085
Naval Medical Center - San Diego
San Diego, California, 92134
UCSF Medical Center-Mount Zion
San Francisco, California, 94115
Nanticoke Memorial Hospital
Seaford, Delaware, 19973
Greenville Health System Cancer Institute-Seneca
Seneca, South Carolina, 29672
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Northern Indiana Cancer Research Consrtium
South Bend, Indiana, 46628
Greenville Health System Cancer Institute-Spartanburg
Spartanburg, South Carolina, 29307
Illinois CancerCare- Spring Valley
Spring Valley, Illinois, 61362
Saint Margaret's Hospital
Spring Valley, Illinois, 61362
Springfield Hospital
Springfield, Vermont, 05156
Washington University School of Medicine
St Louis, Missouri, 63110
Missouri Baptist Cancer Center
St Louis, Missouri, 63131
Missouri Baptist Medical Center
St Louis, Missouri, 63131
Arch Medical Services, Incorporated at Center for Cancer Care and Research
St Louis, Missouri, 63141
Center for Cancer Care and Research
St Louis, Missouri, 63141
Comprehensive Cancer Care, PC
St Louis, Missouri, 63141
Stony Brook University Medical Center
Stony Brook, New York, 11794
Hematology Oncology Associates of Central New York-East Syracuse
Syracuse, New York, 13057
Saint Joseph's Hospital Health Center
Syracuse, New York, 13203
State University of New York Upstate Medical University
Syracuse, New York, 13210
SUNY Upstate Medical University Hospital
Syracuse, New York, 13210
Syracuse Veterans Administration Medical Center
Syracuse, New York, 13210
Veterans Affairs Medical Center - Syracuse
Syracuse, New York, 13210
Cancer Institute of New Jersey at Cooper - Voorhees
Voorhees Township, New Jersey, 08043
Washington Hospital Center
Washington D.C., District of Columbia, 20010
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
Washington D.C., District of Columbia, 20057
White River Junction Veteran Administration Medical Center
White River Junction, Vermont, 05009
Saint Francis Hospital - Wilmington
Wilmington, Delaware, 19805
Wilson Medical Center
Wilson, North Carolina, 27893
Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157-1096
Commonwealth Hematology Oncology PC-Worcester, Worcester
Worcester, Massachusetts, 01605
University of Massachusetts Medical School
Worcester, Massachusetts, 01655
About this study
Official title: Molecular and Cytogenetic Monitoring of CML - A Mandatory Companion to CALGB 19804
RATIONALE: Studying samples of blood and bone marrow from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood and bone marrow samples in patients with chronic myelogenous leukemia enrolled on a CALGB clinical trial.
Read the detailed description
OBJECTIVES:
- Monitor molecular response rates of patients receiving treatment for chronic myelogenous leukemia by quantitative reverse transcription polymerase chain reaction (RT-PCR) and quantitative Southern blot monitoring of blood samples.
- Compare quantitative RT-PCR and quantitative Southern blot results with marrow cytogenetics at the time of complete molecular response in these patients.
- Monitor the frequency of residual disease in patients who achieve a complete blood Southern blot and marrow cytogenetic response (eradication of BCR/ABL by Southern blot and absence of the Philadelphia chromosome by cytogenetics).
OUTLINE: Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.
Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 1.5 years.
- Conditions
- Leukemia
- Being tested
- DNA analysis, Southern blotting, cytogenetic analysis, polymerase chain reaction
- Keywords
- chronic myelogenous leukemia
- Medical subject headings
- Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DNA analysisGenetic
Southern blottingGenetic
cytogenetic analysisGenetic
Also called Laboratory Biomarker Analysis
Correlative studies
polymerase chain reactionGenetic
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.
Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis. Receives: Genetic: DNA analysis; Genetic: Southern blotting; Genetic: cytogenetic analysis; Genetic: polymerase chain reaction |
What is being measured
The primary outcome is the main question the study is designed to answer.
Distribution response
Measured: Up to 1.5 years
Distribution of cytogenetic response
Measured: Up to 1.5 years
Distribution of RT-PCR response or Southern blot response
Measured: Up to 1.5 years
Frequency of residual disease in patients who have achieved a complete response
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2009 (estimated)
- Study start15 Dec 1998
- Primary completionFeb 2001
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LeukemiaStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Responsible party
- Sponsor
- Investigators
- Wendy Stock, MD, Study chair, University of Chicago
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01004640
- Sponsor's protocol ID
- CALGB-29801
- Other IDs
- U10CA031946, U10CA180821, CDR0000078595
- Status last verified
- Sep 2023
- First submitted
- 29 Oct 2009
- Last updated
- 14 Sep 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Molecular and Cytogenetic Monitoring of CML - A Mandatory Companion to CALGB 19804
- ClinicalTrials.gov ID
- NCT01004640
- Acronym / sponsor ID
- CALGB-29801
- Conditions
- Leukemia
- Keywords
- chronic myelogenous leukemia
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- Study start
- 15 Dec 1998 (actual)
- Primary completion
- Feb 2001 (actual)
- First posted
- 30 Oct 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Studying samples of blood and bone marrow from patients with cancer may help doctors identify biomarkers related to cancer.
PURPOSE: This research study is looking at blood and bone marrow samples in patients with chronic myelogenous leukemia enrolled on a CALGB clinical trial.
Detailed description
OBJECTIVES:
- Monitor molecular response rates of patients receiving treatment for chronic myelogenous leukemia by quantitative reverse transcription polymerase chain reaction (RT-PCR) and quantitative Southern blot monitoring of blood samples.
- Compare quantitative RT-PCR and quantitative Southern blot results with marrow cytogenetics at the time of complete molecular response in these patients.
- Monitor the frequency of residual disease in patients who achieve a complete blood Southern blot and marrow cytogenetic response (eradication of BCR/ABL by Southern blot and absence of the Philadelphia chromosome by cytogenetics).
OUTLINE: Peripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected.
Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis.
PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study within 1.5 years.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Group 1 | – | Genetic: DNA analysis, Genetic: Southern blotting, Genetic: cytogenetic analysis, Genetic: polymerase chain reactionPeripheral blood samples and bone marrow aspirates are collected at baseline and at 3, 6, and 9 months after starting therapy. If patient continues to receive protocol treatment after 9 months, additional peripheral blood samples are collected every 6 months and bone marrow aspirates are taken annually. In the event of disease progression (blast crisis), an additional peripheral blood sample and bone marrow aspirate are collected. Samples are examined by quantitative Southern blot analysis with probes to BCR, quantitative reverse transcriptase-polymerase chain reaction analysis for BCR/ABL fusion transcripts, and cytogenetic analysis. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- PATIENTS ENTERED ONTO CALGB TREATMENT STUDIES FOR CML
Key inclusion criteria (3 listed)
- Clinical diagnosis of chronic myelogenous leukemia (CML)
- Concurrent enrollment on a CALGB treatment protocol for newly diagnosed or previously treated CML (e.g, CLB-19804)
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DNA analysis | Genetic | Group 1 |
| Southern blotting | Genetic | Group 1 |
| cytogenetic analysisAlso: Laboratory Biomarker AnalysisCorrelative studies | Genetic | Group 1 |
| polymerase chain reaction | Genetic | Group 1 |
Primary outcome
Distribution response
Time frame: Up to 1.5 years
Distribution of cytogenetic response
Time frame: Up to 1.5 years
Distribution of RT-PCR response or Southern blot response
Time frame: Up to 1.5 years
Frequency of residual disease in patients who have achieved a complete response
Time frame: Up to 12 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2023.
Related trials for Leukemia
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 1
A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML
AML (Acute Myeloid Leukemia)
RecruitingPhase 1
Vididencel in CML-CP Patients With MRD
CML (Chronic Myelogenous Leukemia)
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Wendy Stock, MD study chair
University of Chicago
161 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Leukemia, run by Alliance for Clinical Trials in Oncology at 161 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 161 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Distribution response (time frame: Up to 1.5 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2023.